Aqueous humor and plasma concentrations of ciprofloxacin and moxifloxacin following topical ocular administration in ophthalmologically normal horses

Alison B. Clode Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27606.

Search for other papers by Alison B. Clode in
Current site
Google Scholar
PubMed
Close
 DVM
,
Jennifer L. Davis Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27606.

Search for other papers by Jennifer L. Davis in
Current site
Google Scholar
PubMed
Close
 DVM, PhD
,
Jacklyn Salmon Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27606.

Search for other papers by Jacklyn Salmon in
Current site
Google Scholar
PubMed
Close
 BS
,
Heath LaFevers Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27606.

Search for other papers by Heath LaFevers in
Current site
Google Scholar
PubMed
Close
 BS
, and
Brian C. Gilger Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27606.

Search for other papers by Brian C. Gilger in
Current site
Google Scholar
PubMed
Close
 DVM, MS

Abstract

Objective—To determine the degree of ocular penetration and systemic absorption of commercially available topical ophthalmic solutions of 0.3% ciprofloxacin and 0.5% moxifloxacin following repeated topical ocular administration in ophthalmologically normal horses.

Animals—7 healthy adult horses with clinically normal eyes as evaluated prior to each treatment.

Procedures—6 horses were used for assessment of each antimicrobial, and 1 eye of each horse was treated with topically administered 0.3% ciprofloxacin or 0.5% moxifloxacin (n = 6 eyes/drug) every 4 hours for 7 doses. Anterior chamber paracentesis was performed 1 hour after the final dose was administered, and blood samples were collected at 24 (immediately after the final dose), 24.25, 24.5, and 25 hours (time of aqueous humor [AH] collection). Plasma and AH concentrations of ciprofloxacin or moxifloxacin were determined by use of high-performance liquid chromatography.

Results—Mean ± SD AH concentrations of ciprofloxacin and moxifloxacin were 0.009 ± 0.008 μg/mL and 0.071 ± 0.029 μg/mL, respectively. The AH moxifloxacin concentrations were significantly greater than those of ciprofloxacin. Mean ± SD plasma concentrations of ciprofloxacin were less than the lower limit of quantification. Moxifloxacin was detected in the plasma of all horses at all sample collection times, with a peak value of 0.015 μg/mL at 24 and 24.25 hours, decreasing to < 0.004 μg/mL at 25 hours.

Conclusions and Clinical Relevance—Moxifloxacin was better able to penetrate healthy equine corneas and reach measurable AH concentrations than was ciprofloxacin, suggesting moxifloxacin might be of greater value in the treatment of deep corneal or intraocular bacterial infections caused by susceptible organisms. Topical administration of moxifloxacin also resulted in detectable plasma concentrations.

Abstract

Objective—To determine the degree of ocular penetration and systemic absorption of commercially available topical ophthalmic solutions of 0.3% ciprofloxacin and 0.5% moxifloxacin following repeated topical ocular administration in ophthalmologically normal horses.

Animals—7 healthy adult horses with clinically normal eyes as evaluated prior to each treatment.

Procedures—6 horses were used for assessment of each antimicrobial, and 1 eye of each horse was treated with topically administered 0.3% ciprofloxacin or 0.5% moxifloxacin (n = 6 eyes/drug) every 4 hours for 7 doses. Anterior chamber paracentesis was performed 1 hour after the final dose was administered, and blood samples were collected at 24 (immediately after the final dose), 24.25, 24.5, and 25 hours (time of aqueous humor [AH] collection). Plasma and AH concentrations of ciprofloxacin or moxifloxacin were determined by use of high-performance liquid chromatography.

Results—Mean ± SD AH concentrations of ciprofloxacin and moxifloxacin were 0.009 ± 0.008 μg/mL and 0.071 ± 0.029 μg/mL, respectively. The AH moxifloxacin concentrations were significantly greater than those of ciprofloxacin. Mean ± SD plasma concentrations of ciprofloxacin were less than the lower limit of quantification. Moxifloxacin was detected in the plasma of all horses at all sample collection times, with a peak value of 0.015 μg/mL at 24 and 24.25 hours, decreasing to < 0.004 μg/mL at 25 hours.

Conclusions and Clinical Relevance—Moxifloxacin was better able to penetrate healthy equine corneas and reach measurable AH concentrations than was ciprofloxacin, suggesting moxifloxacin might be of greater value in the treatment of deep corneal or intraocular bacterial infections caused by susceptible organisms. Topical administration of moxifloxacin also resulted in detectable plasma concentrations.

Contributor Notes

Supported by a College of Veterinary Medicine Research Grant.

The authors thank Drs. Richard McMullen and Diana Pate for assistance with sample collection.

Address correspondence to Dr. Clode (abclode@ncsu.edu).
  • 1.

    Andrew S, Willis A. Diseases of the cornea and sclera. In: Gilger B, ed. Equine ophthalmology. St Louis: Elsevier Saunders, 2005;157251.

    • Search Google Scholar
    • Export Citation
  • 2.

    Ollivier FJ, Brooks DE, Kallberg ME, et alEvaluation of various compounds to inhibit activity of matrix metalloproteinases in the tear film of horses with ulcerative keratitis. Am J Vet Res 2003;64:10811087.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 3.

    Strubbe DT, Brooks DE, Schultz GS, et alEvaluation of tear film proteinases in horses with ulcerative keratitis. Vet Ophthalmol 2000;3:111119.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 4.

    Sauer P, Andrew SE, Lassaline M, et alChanges in antibiotic resistance in equine bacterial ulcerative keratitis (1991–2000): 65 horses. Vet Ophthalmol 2003;6:309313.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 5.

    Keller RL, Hendrix DV. Bacterial isolates and antimicrobial susceptibilities in equine bacterial ulcerative keratitis (1993–2004). Equine Vet J 2005;37:207211.

    • Search Google Scholar
    • Export Citation
  • 6.

    Moore CP, Fales WH, Whittington P, et alBacterial and fungal isolates from Equidae with ulcerative keratitis. J Am Vet Med Assoc 1983;182:600603.

    • Search Google Scholar
    • Export Citation
  • 7.

    Regnier A. Clinical pharmacology and therapeutics part 1: drug delivery. In: Gelatt K, ed. Veterinary ophthalmology. 4th ed. Ames, Iowa: Blackwell, 2007;271287.

    • Search Google Scholar
    • Export Citation
  • 8.

    Clode AB, Davis JL, Salmon J, et alEvaluation of concentration of voriconazole in aqueous humor after topical and oral administration in horses. Am J Vet Res 2006;67:296301.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 9.

    Kim DH, Stark WJ, O'Brien TP. Ocular penetration of moxifloxacin 0.5% and gatifloxacin 0.3% ophthalmic solutions into the aqueous humor following topical administration prior to routine cataract surgery. Curr Med Res Opin 2005;21:9394.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 10.

    McCulley J, Caudle D, Aronowicz J, et alFourth-generation fluoroquinolone penetration into the aqueous humor in humans. Ophthalmology 2006;113:955959.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 11.

    Robertson SM, Curtis MA, Schlech BA, et alOcular pharmacokinetics of moxifloxacin after topical treatment of animals and humans. Surv Ophthalmol 2005;50(suppl 1):S32S45.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 12.

    Sakamoto H, Sakamoto M, Hata Y, et alAqueous and vitreous penetration of levofloxacin after topical and/or oral administration. Eur J Ophthalmol 2007;17:372376.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 13.

    Solomon R, Donnenfeld E, Perry H, et alPenetration of topically applied gatifloxacin 0.3%, moxifloxacin 0.5%, and ciprofloxacin 0.3% into the aqueous humor. Ophthalmology 2005;112:466469.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 14.

    Asbell PA, Colby KA, Deng S, et alOcular TRUST: nationwide antimicrobial susceptibility patterns in ocular isolates. Am J Ophthalmol 2008;145:951958.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 15.

    Duggirala A, Joseph J, Sharma S, et alActivity of newer fluoroquinolones against gram-positive and gram-negative bacteria isolated from ocular infections: an in vitro comparison. Indian J Ophthalmol 2007;55:1519.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 16.

    Afshari NA, Ma JJ, Duncan SM, et alTrends in resistance to ciprofloxacin, cefazolin, and gentamicin in the treatment of bacterial keratitis. J Ocul Pharmacol Ther 2008;24:217223.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 17.

    Kotlus BS, Wymbs RA, Vellozzi EM, et alIn vitro activity of fluoroquinolones, vancomycin, and gentamicin against methicillin-resistant Staphylococcus aureus ocular isolates. Am J Ophthalmol 2006;142:726729.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 18.

    Schlech BA, Alfonso E. Overview of the potency of moxifloxacin ophthalmic solution 0.5% (VIGAMOX). Surv Ophthalmol 2005;50:S7S15.

  • 19.

    Soussy CJ, Nguyen J, Goldstein F, et alIn vitro antibacterial activity of moxifloxacin against hospital isolates: a multicentre study. Clin Microbiol Infect 2003;9:9971005.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 20.

    Yagci R, Oflu Y, Dinçel A, et alPenetration of second-, third-, and fourth-generation topical fluoroquinolone into aqueous and vitreous humour in a rabbit endophthalmitis model. Eye (Lond) 2007;21:990994.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 21.

    Michau T. Equine ocular examination: basic and advanced diagnostic techniques. In: Gilger B, ed. Equine ophthalmology. St Louis: Elsevier Saunders, 2005;162.

    • Search Google Scholar
    • Export Citation
  • 22.

    Papich MG, Van Camp SD, Cole JA, et alPharmacokinetics and endometrial tissue concentrations of enrofloxacin and the metabolite ciprofloxacin after i.v. administration of enrofloxacin to mares. J Vet Pharmacol Ther 2002;25:343350.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 23.

    Gardner SY, Davis JL, Jones SL, et alMoxifloxacin pharmacokinetics in horses and disposition into phagocytes after oral dosing. J Vet Pharmacol Ther 2004;27:5760.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 24.

    Thompson A. Ocular toxicity of fluoroquinolones. Clin Experiment Ophthalmol 2007;35:566577.

  • 25.

    Noecker R. Effects of common ophthalmic preservatives on ocular health. Adv Ther 2001;18:205215.

  • 26.

    Andrew SE, Ramsey DT, Hauptman JG, et alDensity of corneal endothelial cells and corneal thickness in eyes of euthanatized horses. Am J Vet Res 2001;62:479482.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 27.

    Edelhauser H, Ubels J. The cornea and the sclera. In: Kaufman P, Alm A, eds. Adler's physiology of the eye. 10th ed. St Louis: Mosby, 2003;47114.

    • Search Google Scholar
    • Export Citation
  • 28.

    Biros DJ, Brooks DE, Brown MP, et alRegional and zonal variations in the sulfation patterns of chondroitin sulfate in normal equine corneal stroma. Am J Vet Res 2002;63:143147.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 29.

    Gilger BC, Reeves KA, Salmon JH. Ocular parameters related to drug delivery in the canine and equine eye: aqueous and vitreous humor volume and scleral surface area and thickness. Vet Ophthalmol 2005;8:265269.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 30.

    Gum G, Gelatt K, Esson D. Physiology of the eye. In: Gelatt K, ed. Veterinary ophthalmology. Ames, Iowa: Blackwell, 2007;149182.

  • 31.

    Kowalski RP, Dhaliwal DK, Karenchak LM, et alGatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates. Am J Ophthalmol 2003;136:500505.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 32.

    Mather R, Karenchak L, Romanowski E, et alFourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics. Am J Ophthalmol 2002;133:463466.

    • Search Google Scholar
    • Export Citation
  • 33.

    Schoenwald R. The control of drug bioavailability from ophthalmic dosage forms. In: Smolen V, Ball L, eds. Controlled drug bioavailability. New York: John Wiley & Sons, 1985;257.

    • Search Google Scholar
    • Export Citation
  • 34.

    DeSantis L, Patil P. Pharmacokinetics. In: Mauger T, Craig E, eds. Havener's ocular pharmacology. 6th ed. St Louis: Mosby, 1994;2252.

  • 35.

    Weese JS, Kaese HJ, Baird JD, et alSuspected ciprofloxacin-induced colitis in four horses. Equine Vet Educ 2002;14:182186.

Advertisement